Related Experiment Video
Updated: Jun 9, 2026
Quantitative, Real-time Analysis of Base Excision Repair Activity in Cell Lysates Utilizing Lesion-specific Molecular Beacons
Published on: August 6, 2012
Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of
Young-Hee Oh1, Youngwook Kim, Young-Pil Kim
1Department of Biological Sciences, KAIST (Korea Advanced Institute of Science and Technology), Daejon, Korea.
Abstract:
A secondary mutation (T790M) in epidermal growth factor receptor (EGFR) is a hallmark of acquired resistance to EGFR inhibitors used to treat non-small-cell lung cancer (NSCLC). Therefore, identifying the T790M mutation is crucial to guide treatment decisions. Given that DNA sequencing methods are time-consuming and insensitive, we developed and investigated the feasibility of using molecular beacons for the detection of the T790M mutation in EGFR. A molecular beacon complementary to the region of the secondary EGFR mutation (T790M) was designed and used in NSCLC samples bearing drug-sensitive and -resistant EGFR mutations. For a rapid and simple assay, we attempted to use the molecular beacon with real-time PCR and in situ fluorescence imaging. The ability of the designed molecular beacon to specifically detect the T790M mutation of EGFR was tested for samples from two patients with drug resistance and compared with conventional DNA sequencing methods. The molecular beacon successfully detected the T790M mutation in patient samples with drug resistance. The sensitivity of the molecular beacon, which detected as little as 2% of genomic DNA from the drug-resistant cells (H1975), was much higher than direct sequencing. Furthermore, in situ fluorescence imaging with the molecular beacon gave rise to a distinguishable signal for the T790M mutation in drug-resistant cells. The molecular beacon-based approach enabled rapid and sensitive detection of the EGFR mutation (T790M) in NSCLC with in situ fluorescence imaging, which can be directed to determine various treatment options in patients with cancer.
Insights
A new molecular beacon test rapidly and sensitively detects the T790M mutation in epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) patients. This method aids in guiding treatment decisions for drug-resistant lung cancer.
Area of Science:
- Molecular biology
- Genetics
- Oncology
Background:
- Acquired resistance to EGFR inhibitors in non-small-cell lung cancer (NSCLC) is often due to the T790M secondary mutation in the epidermal growth factor receptor (EGFR).
- Accurate and timely identification of the T790M mutation is critical for selecting effective treatment strategies.
- Conventional DNA sequencing methods for mutation detection can be slow and lack sensitivity.
Purpose of the Study:
- To develop and assess the feasibility of using molecular beacons for the rapid and sensitive detection of the EGFR T790M mutation in NSCLC.
- To compare the performance of the molecular beacon assay with conventional DNA sequencing.
Main Methods:
- Design of a molecular beacon specific to the EGFR T790M mutation region.
- Application of the molecular beacon in real-time PCR and in situ fluorescence imaging assays.
- Testing the assay on NSCLC patient samples with known drug-sensitive and drug-resistant EGFR mutations, including comparison with direct sequencing.
Main Results:
- The molecular beacon assay successfully detected the T790M mutation in patient samples exhibiting drug resistance.
- The assay demonstrated high sensitivity, detecting as little as 2% of genomic DNA from drug-resistant cells (H1975), surpassing direct sequencing.
- In situ fluorescence imaging provided a clear signal for the T790M mutation in resistant cells.
Conclusions:
- The molecular beacon-based approach offers a rapid, sensitive, and effective method for detecting the EGFR T790M mutation in NSCLC.
- This technique, combined with in situ fluorescence imaging, can aid in determining optimal treatment options for cancer patients.
